E
Eric Lu
Researcher at Oregon Health & Science University
Publications - 15
Citations - 495
Eric Lu is an academic researcher from Oregon Health & Science University. The author has contributed to research in topics: Prostate cancer & Enzalutamide. The author has an hindex of 8, co-authored 15 publications receiving 320 citations. Previous affiliations of Eric Lu include University of Nevada, Reno School of Medicine & University of Nevada, Reno.
Papers
More filters
Journal ArticleDOI
Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors.
David A. Quigley,Joshi J. Alumkal,Alexander W. Wyatt,Vishal Kothari,Adam Foye,Paul Lloyd,Rahul Aggarwal,Won Kim,Eric Lu,Jacob Schwartzman,Kevin Beja,Matti Annala,Rajdeep Das,Morgan E. Diolaiti,Colin C. Pritchard,George Thomas,Scott A. Tomlins,Karen E. Knudsen,Christopher J. Lord,Charles J. Ryan,Jack F. Youngren,Tomasz M. Beer,Alan Ashworth,Eric J. Small,Felix Y. Feng +24 more
TL;DR: BRCA2 reversion mutations in patients with prostate cancer with metastatic disease who developed resistance to talazoparib and olaparib are identified and it is shown that PARPi resistance is highly multiclonal and that cfDNA allows monitoring for PAR Pi resistance.
Journal ArticleDOI
Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer.
William S. Chen,William S. Chen,Rahul Aggarwal,Li Zhang,Shuang G. Zhao,George Thomas,Tomasz M. Beer,David A. Quigley,Adam Foye,Denise Playdle,Jiaoti Huang,Paul Lloyd,Eric Lu,Duanchen Sun,Xiangnan Guan,Matthew Rettig,Matthew Rettig,Martin E. Gleave,Christopher P. Evans,Jack F. Youngren,Lawrence D. True,Primo N. Lara,Vishal Kothari,Zheng Xia,Kim N. Chi,Robert E. Reiter,Christopher G. Maher,Felix Y. Feng,Eric J. Small,Joshi J. Alumkal +29 more
TL;DR: Using whole-genome sequencing to assess the association between key driver gene alterations and overall survival (OS) and whole-transcriptome RNA sequencing to identify genomic drivers of enzalutamide resistance sheds new light on clinically relevant genomic alterations in mCRPC and provides a roadmap for the development of new personalized treatment regimens in m CRPC.
Journal ArticleDOI
Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance
Joshi J. Alumkal,Duanchen Sun,Eric Lu,Tomasz M. Beer,George Thomas,Emile Latour,Rahul Aggarwal,Jeremy Cetnar,Charles J. Ryan,Shaadi Tabatabaei,Shawna Bailey,Claire B Turina,David A. Quigley,Xiangnan Guan,Adam Foye,Jack F. Youngren,Joshua Urrutia,Jiaoti Huang,Alana S. Weinstein,Verena Friedl,Matthew Rettig,Robert E. Reiter,Daniel E. Spratt,Martin E. Gleave,Christopher P. Evans,Joshua M. Stuart,Yiyi Chen,Felix Y. Feng,Eric J. Small,Owen N. Witte,Zheng Xia +30 more
TL;DR: Transcriptional profiling identified specific gene sets—including those linked to reduced AR transcriptional activity and a stemness program—that were activated in nonresponders, suggesting that patients whose tumors harbor this program should be considered for clinical trials testing rational agents to overcome de novo enzalutamide resistance.
Journal ArticleDOI
When to Stop Eculizumab in Complement-Mediated Thrombotic Microangiopathies.
TL;DR: Evaluated literature on eculizumab cessation in atypical hemolytic uremic syndrome and secondary HUS suggests indefinite therapy is reasonable and that patients who choose to stop should be closely monitored.
Journal ArticleDOI
The Safety of Low-Molecular-Weight Heparin during and after Pregnancy
TL;DR: Overall, current evidence behind these risks is limited, and this review suggests areas of further study moving forward.